A rare USPTO Appeals Review Panel dissects PTAB's bold ODP reversal. Professors Mark Lemley and Lisa Oullette fire back—CAFC history demands examiners' rejections stand.
Picture this: 85% of patents hitting the PTAB are already tangled in federal court. Congress's America Invents Act didn't streamline challenges—it rigged them against inventors.
Imagine defending your patent without the endless IPR gauntlet. USPTO's latest stats show institutions down 43%, handing real wins to innovators buried in PTAB backlog.
Small inventors betting on the STRONGER Patents Act might find their patents safer from IPR attacks—or ensnared in legal gray zones. Vague rules on 'validity decisions' could let trolls thrive while genuine innovators wait.
Lab researchers and biotech founders just got a stark reminder: CRISPR's patent throne belongs to Broad Institute. PTAB's latest ruling crushes UC's priority bid, reshaping who pays to edit genes.